Skip to main content
    C

    Coherus BioSciences Inc (CHRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.51
    -0.02 (-3.73%)

    Market Cap: $81.21M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Coherus BioSciences Inc (CHRS) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Coherus BioSciences (CHRS) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Coherus BioSciences reported EPS of -$0.25, below the -$0.22 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    28%(11/40)
    Avg Surprise
    -8.47%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.22
    Range-$0.28 - -$0.19
    9 analysts
    Revenue Consensus
    $17.43M
    Range$15.58M - $19.84M
    8 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.20
    Range-$0.20 - -$0.20
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.21+4.8%
    60d ago-$0.26+23.1%
    30d ago-$0.26+23.1%
    7d ago-$0.26+23.1%
    Current-$0.20
    Revenue Consensus
    $18.49M
    Range$16.40M - $20.50M
    4 analysts

    Next Report

    CHRS has an expected report date of Mar 8, 2027.

    CHRS Earnings Call

    The latest CHRS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CHRS beat 11, missed 28 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $14.27M, up 23.3% from $11.57M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.25-$0.22N/A-13.64%MissN/A12 up, 0 downNov 9, 2026$14.27M
    Jun 30, 2026-$0.22-$0.16-$0.31 - $0.08-37.50%MissN/A22 up, 0 downAug 5, 2026$14.31M
    Mar 31, 2026-$0.25-$0.26-$0.35 - -$0.18+3.85%BeatN/A20 up, 0 downMay 11, 2026$12.31M
    Dec 31, 2025-$0.34-$0.34N/A-0.53%MissN/A10 up, 1 downMar 9, 2026$12.75M
    Sep 30, 2025-$0.33-$0.29-$0.32 - -$0.26-13.79%MissN/A20 up, 1 downNov 6, 2025$11.57M
    Jun 30, 2025-$0.39-$0.25-$0.33 - -$0.17-56.00%MissN/A30 up, 1 downAug 7, 2025$10.25M
    Mar 31, 2025-$0.35-$0.22N/A-59.09%MissN/A20 up, 0 downMay 12, 2025$7.60M
    Dec 31, 2024-$0.28-$0.13-$0.23 - $0.06-114.56%MissN/A50 up, 1 downMar 10, 2025$7.73M
    Sep 30, 2024-$0.01-$0.11-$0.28 - $0.02+90.91%BeatN/A52 up, 0 downNov 6, 2024$6.05M
    Jun 30, 2024-$0.14-$0.26-$0.38 - -$0.23+46.15%BeatN/A31 up, 0 downAug 8, 2024$10.30M
    Mar 31, 2024-$0.32-$0.21-$0.37 - -$0.05-52.38%MissN/A50 up, 0 downMay 9, 2024$2.31M
    Dec 31, 2023-$0.62-$0.12-$0.37 - $0.52-416.67%MissN/A61 up, 0 downMar 13, 2024$91.52M
    Sep 30, 2023-$0.27-$0.24-$0.67 - $0.03-12.50%MissN/A70 up, 0 downNov 6, 2023$74.57M
    Jun 30, 2023-$0.38-$0.44-$0.61 - -$0.21+13.64%BeatN/A73 up, 0 downAug 2, 2023$58.72M
    Mar 31, 2023-$0.80-$0.47-$1.00 - -$0.18-70.21%MissN/A73 up, 0 downMay 8, 2023$32.44M
    Dec 31, 2022-$0.60-$0.84-$1.52 - -$0.62+28.57%BeatN/A60 up, 0 downMar 6, 2023$45.35M
    Sep 30, 2022-$0.96-$0.61-$0.68 - -$0.48-57.38%MissN/A52 up, 0 downNov 8, 2022$45.42M
    Jun 30, 2022-$0.47-$0.73-$0.79 - -$0.49+35.62%BeatN/A51 up, 0 downAug 4, 2022$60.15M
    Mar 31, 2022-$1.00-$0.65N/A-53.85%MissN/A40 up, 1 downMay 5, 2022$60.12M
    Dec 31, 2021-$0.60-$0.54-$0.79 - -$0.25-11.11%Miss-600.0%5N/AFeb 17, 2022$73.37M
    Sep 30, 2021-$0.49-$0.29-$0.30 - -$0.13-68.97%Miss-248.5%5N/ANov 8, 2021$82.50M
    Jun 30, 2021-$0.40-$0.15-$0.25 - -$0.05-166.67%Miss-157.1%4N/AAug 5, 2021$87.64M
    Mar 31, 2021-$0.23$0.11-$0.03 - $0.13-309.09%Miss-147.9%6N/AMay 6, 2021$83.03M
    Dec 31, 2020$0.12$0.23$0.13 - $0.40-47.83%Miss-78.6%10N/AFeb 24, 2021$110.42M
    Sep 30, 2020$0.33$0.34$0.23 - $0.76-2.94%Miss-47.6%10N/ANov 5, 2020$113.55M
    Jun 30, 2020$0.70$0.29$0.20 - $0.73+141.38%Beat+118.7%9N/AAug 6, 2020$135.67M
    Mar 31, 2020$0.48$0.48$0.36 - $0.740.00%In lineN/A8N/AMay 7, 2020$116.18M
    Dec 31, 2019$0.56$0.72$0.64 - $0.82-22.22%MissN/A8N/AFeb 27, 2020$123.86M
    Sep 30, 2019$0.63$0.42$0.28 - $0.83+50.00%BeatN/A8N/ANov 6, 2019$111.68M
    Jun 30, 2019$0.32-$0.04-$0.36 - $0.29+900.00%BeatN/A7N/AAug 1, 2019$83.43M
    Mar 31, 2019-$0.29-$0.46-$0.52 - -$0.38+36.96%BeatN/A6N/AMay 9, 2019$37.10M
    Dec 31, 2018-$0.92-$0.86-$0.90 - -$0.81-6.98%MissN/A4N/AFeb 28, 2019N/A
    Sep 30, 2018-$0.87-$0.79-$0.82 - -$0.70-10.13%MissN/A5N/ANov 8, 2018N/A
    Jun 30, 2018-$0.68-$0.65-$0.76 - -$0.53-4.62%MissN/A5N/AAug 8, 2018N/A
    Mar 31, 2018-$0.74-$0.70-$0.85 - -$0.55-5.71%MissN/A5N/AMay 10, 2018N/A
    Dec 31, 2017-$0.84-$0.81-$1.03 - -$0.49-3.70%MissN/A6N/AMar 8, 2018$1.56M
    Sep 30, 2017-$1.09-$0.85N/A-28.24%Miss-165.3%N/AN/ANov 6, 2017N/A
    Jun 30, 2017-$1.08-$1.39N/A+22.30%BeatN/AN/AN/AAug 7, 2017$1.40M
    Mar 31, 2017-$1.54-$1.43N/A-7.69%MissN/AN/AN/AMay 8, 2017$161000
    Dec 31, 2016-$1.71-$1.11N/A-54.05%MissN/AN/AN/AMar 13, 2017$844000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.41, after -$0.75 the year before. It was -$3.43 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.41N/A
    Dec 31, 2024-$0.75N/A
    Dec 31, 2023-$2.07N/A
    Dec 31, 2022-$3.03N/A
    Dec 31, 2021-$1.72-205.5%
    Dec 31, 2020$1.63+33.6%
    Dec 31, 2019$1.22N/A
    Dec 31, 2018-$3.21N/A
    Dec 31, 2017-$4.55N/A
    Dec 31, 2016-$3.43N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,25912
    2026Q2Jun 30, 20265,73312
    2026Q1Mar 31, 20266,27513
    2025Q4Dec 31, 20257,70512
    2025Q3Sep 30, 20256,78313
    2025Q2Jun 30, 20256,21213
    2025Q1Mar 31, 20257,76012
    2024Q4Dec 31, 20246,81814

    2026Q3 Earnings Call

    Opening remarks

    Carrie Graham Investor Relations Thank you, Heidi. Third quarter earnings conference call. Joining me are Denny Lanfear, Chief Executive Officer of Coherus; Dr. Rosh Dias, Chief Medical Officer; Dr. Theresa Lavallee, Chief Scientific and Development Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus' current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly report on Form 10-Q for more information on risks and uncertainties. And now I'll turn the call over to Denny.

    Dennis Lanfear CEO Thank you, Carrie, and good afternoon, everyone. Thank you for joining us on our third quarter 2026 earnings call. As you know, we have spent the last few years transforming Coherus from a biosimilars company into an innovative oncology company focused on overcoming immune resistance in cancer. We've made substantial progress in reducing our debt, lowering our operating expenses, establishing LOQTORZI in the market, and advancing our clinical pipeline. We've conducted key clinical trials and developed sufficient data to set future development direction for our tagmokitug program and select the go-forward dose. Today, I will discuss three strategic alternatives designed to make Coherus a financially self-sustaining innovative oncology company with best-in-class and first-in-class products by the end of 2027. First, the strategic prioritization of esophageal cancer as our focus for best-in-disease development of tagmokitug. Second, the structural and financial benefits that flow directly from this prioritization. And then finally, our emphasis on driving LOQTORZI revenues over the next four or five quarters to a level where they can fully support the company's core cash burn. When we launched the tagmokitug clinical program, it was with a clear expectation that we would select the most promising area for continued development. This is exactly what we have done. As we reported on October 28, over the last two years, we have explored a wide range of mucosal system cancers, from head and neck, esophageal, gastric, and colorectal, across various lines of therapy to understand where Treg depletion might best be advanced as combination therapy. The emerging data from this very systematic clinical investigation demonstrated that esophageal cancer comprises a best-in-disease opportunity across first and second lines of therapy. Accordingly, going forward, we will be sharply focusing our tagmokitug development efforts there, as this provides a substantial number of benefits. First, providing a treatment alternative to patients confronting a particularly difficult cancer with poor prognosis.

    Frequently Asked Questions About CHRS

    When is Coherus BioSciences's next earnings date?

    Coherus BioSciences's next earnings report is expected for Mar 8, 2027.

    Did CHRS beat earnings estimates last quarter?

    No. Coherus BioSciences reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.22 estimate by 13.64%.

    What EPS do analysts expect from CHRS next quarter?

    The consensus EPS estimate for Coherus BioSciences for the quarter ending Dec 31, 2026 is -$0.22 from 9 analysts, with estimates from -$0.28 to -$0.19.

    How often does CHRS beat earnings estimates?

    Coherus BioSciences beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -36.41%.